



ORAL PRESENTATION

Open Access

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program

A Lazzarin¹, JG Sierra-Madero², M Battegay³, G Mukwaya⁴, R Burnside⁵, D Chapman⁶, J McCracken⁵, S Portsmouth⁶, S Valluri⁶, H Valdez⁶, J Heera^{7*}*From* Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Background

Across the MVC development program, patients who received MVC-containing regimens experienced greater increases in CD4+ cell counts than those observed in comparator arms in primary analyses. Here we present longer term immunological data from this program.

Material and methods

Long-term (96 week) data from subjects with CCR5-tropic HIV infection in the following ongoing MVC studies were included in the analysis: (1) MOTIVATE study (MVC QD and BID vs placebo (PBO), each combined with optimized background therapy in treatment-experienced [TE] subjects); and (2) MERIT study (MVC BID vs EFV, each combined with ZDV/3TC in treatment-naïve [TN] subjects). Additionally, interim week 24 data from the ongoing 96-week 1078 study (MVC QD vs TDF/FTC, each combined with ATV/r in TN subjects)

were summarized. Descriptive statistics are presented for data at baseline and at week 96 (MERIT/MOTIVATE) or week 24 (1078) pertaining to change in CD4+ and CD8+ cells.

Results

Greater increases in CD4+ cells in MVC-containing groups persisted through 96 weeks in the MOTIVATE and MERIT studies, and through 24 weeks in the 1078 study (Table 1). Similarly, changes in CD8+ cells from baseline to weeks 96 or 24 favored MVC-containing regimens in all three studies. In a combined LOCF analysis of patients from all three studies at week 24, CD4+ counts increased by a median 100.5 cells/ μ L in 1260 recipients of MVC-containing regimens, compared with 84.5 cells/ μ L in 631 recipients of comparator regimens; CD8+ counts increased by a median 153 cells/ μ L in the MVC group, compared with a decrease of 61 cells/ μ L in

Table 1

Population	Treatment-experienced			Treatment-naïve			
	MOTIVATE – 96 Weeks			MERIT – 96 Weeks		1078 – 24 Weeks	
Study							
Arm	MVC QD	MVC BID	PBO	MVC BID	EFV	MVC QD	TDF/FTC
N	414	426	209	360	361	60	61
BL HIV RNA (median log ₁₀ cp/mL)	4.86	4.85	4.86	4.88	4.85	4.59	4.66
Baseline CD4 count (median cells/ μ L)	171	167	171	244.3	258.5	344.5	358.0
Baseline CD8 count (median cells/ μ L)	867.5	836.5	820.8	791.5	860.0	859.8	890.0
CD4 change from BL (median cells/ μ L)	89.0	112.5	21.0	224.3	195.0	195.3	173.0
CD8 change from BL (median cells/ μ L)	138.0	157.0	31.5	-3.00	-94.5	4.5	-78.5

⁷Pfizer, 50 Pequot Ave, New London, USA

Full list of author information is available at the end of the article

the comparator group. At week 96, a combined analysis of patients from the MOTIVATE and MERIT studies showed median CD4+ increases from baseline of 129.5 and 100.3 cells/ μ L in the MVC (N=1177) and comparator (N=554) groups, respectively; CD8+ changes were 96 and -72 cells/ μ L, respectively. In all studies, differences in CD4+ and CD8+ counts between treatment groups were independent of differences in viral load changes (data not shown).

Conclusions

Greater increases in CD4+ and CD8+ counts were consistently achieved with MVC-containing regimens, compared to regimens without MVC, and persisted through at least 2 years of therapy in both TN and TE patients. These differences were independent of changes in HIV-1 RNA and are evident with multiple different MVC-containing regimens.

Author details

¹San Raffaele Scientific Institute, Milano, Italy. ²Dept. of Immunology & Infectious Diseases INNSZ, Mexico City, Mexico. ³Univ. Hosp, Basel, Switzerland. ⁴Pfizer Inc, New York, USA. ⁵Pfizer Global Research, New London, USA. ⁶Pfizer Inc, New York, USA. ⁷Pfizer, 50 Pequot Ave, New London, USA.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-O45

Cite this article as: Lazzarin *et al.*: Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O45.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

